Hisamitsu Pharmaceutical Co.,Inc.
4530・Prime Market・Pharmaceuticals
Governance
Company with a Board of Corporate Auditors. The Board of Directors consists of 10 members (including 4 outside directors, a 40% outside ratio), and the Board of Corporate Auditors consists of 4 members (including 2 outside auditors). A voluntary Nomination and Compensation Committee (comprising 2 directors and 3 outside directors), chaired by the Representative Director and President, has been established. Directors serve one-year terms, and the company has adopted an executive officer system. The Board of Directors met 7 times during the fiscal year under review.
Risk Management
Risk management is implemented through a five-committee structure: the Sustainability Promotion Committee (held quarterly in principle), the Compliance Promotion Committee, the Crisis Management Committee (chaired by the President and Representative Director), the Personal Information Protection Committee, and the Disclosure Policy Team. Sustainability-related risks are identified, assessed, and prioritized by the Sustainability Promotion Committee, and are integrated into company-wide risk management through regular reporting to the Board of Directors.
Shareholder Returns
For FY2026 (ending February 2026), the annual dividend is ¥60 per share (interim ¥60, year-end ¥0), with a payout ratio of 22.3%. Share buybacks of ¥12,273 million were conducted. As the company is scheduled to be delisted on May 11, 2026, no dividend forecast for FY2027 (ending February 2027) has been disclosed.
Dividend Policy
For FY2026 (ending February 2026), the annual dividend is ¥60 per share (interim ¥60, year-end ¥0), with total dividends of ¥4,288 million and a payout ratio of 22.3%. This represents a decrease from the previous fiscal year (annual dividend of ¥90, total dividends of ¥6,603 million, payout ratio of 30.4%). As a result of the tender offer by Taiyo Kosan Co., Ltd., the company is scheduled to be delisted on May 11, 2026, and therefore no dividend forecast for FY2027 (ending February 2027) has been disclosed.
ESG
Identified 9 materiality issues in 2021 and is advancing sustainability activities spanning environment, society, and governance overall. Regarding climate change measures, the company has set a target of a 46% reduction in CO2 emissions (Scope 1 and 2) by FY2030 compared to FY2013, and net zero by FY2050; FY2023 results showed a 17.1% reduction (34,439t) across the group as a whole. In terms of human capital, the company discloses a female manager ratio of 9.4% (FY2024), a male childcare leave uptake rate of 54.0%, and an annual paid leave utilization rate of 69.3% (target: 80%). The company has established DE&I promotion, global talent development, and an in-house venture system, among other initiatives.
Last updated: May 23, 2025